Basic and clinical immunologyCanadian 2003 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema
Section snippets
Consensus algorithm
- 1.
Clinical characteristics2
- a.
Recurrent angioedema (swelling) without urticaria (without hiving) that is usually nonpruritic (without itch, although sometimes there is a nonpruritic serpentine erythematous rash).22
- b.
Swelling can affect the extremities, face, trunk, gastrointestinal tract, genitourinary regions, or upper airways (any area of the body can be involved; Fig 1).
- c.
Abdominal symptoms might mimic infantile colic, acute appendicitis, or acute abdomen, and symptoms might include nausea, vomiting,
- a.
References (77)
The pathogenesis of hereditary angioedema
Transfus Apheresis Sci
(2003)Diagnosis and management of hereditary angioedema: an American approach
Transfus Apheresis Sci
(2003)- et al.
A biochemical abnormality in hereditary angioneurotic edema: absence of serum inhibitor of C'1-esterase
Am J Med
(1963) - et al.
Estrogen-dependent inherited angioedema
Transfus Apheresis Sci
(2003) - et al.
Clinical, biochemical and genetic characterization of a novel estrogen-dependent inherited form of angioedema
J Allergy Clin Immunol
(2000) - et al.
Hereditary angioedema with normal C1-inhibitor activity in women
Lancet
(2000) - et al.
Sudden upper airway obstruction in patients with hereditary angioedema
Transfus Apheresis Sci
(2003) - et al.
Management of hereditary angioedema: a Canadian approach
Transfus Apheresis Sci
(2003) - et al.
How do we treat patients with hereditary angioedema
Transfus Apheresis Sci
(2003) - et al.
The Hungarian HAE experience
Transfus Apheresis Sci
(2003)
Safety and efficacy of pasteurized C1 inhibitor concentrate (Berinert P) in hereditary angioedema: a review
Transfus Apheresis Sci
DX-88 and HAE: a developmental perspective
Transfus Apheresis Sci
Protease inhibitors in the treatment of hereditary angioedema
Transfus Apheresis Sci
Tissue archives to track blood borne pathogens in people receiving blood products
Transfus Apheresis Sci
The value of rocket immunoelectrophoresis for C4 activation in the evaluation of patients with angioedema or C1-inhibitor deficiency
J Allergy Clin Immunol
Frequent de novo mutations and exon deletions in the C1 inhibitor gene of patients with angioedema
J Allergy Clin Immunol
Contraindications to the use of ACE inhibitors in patients with C1 esterase inhibitor deficiency
Am J Med
Recurrent episodes of skin angioedema and severe attacks of abdominal pain induced by oral contraceptives or hormone replacement therapy
Am J Med
Hormone replacement therapy in postmenopausal women with essential hypertension increases circulating plasma levels of bradykinin
Am J Hypertens
Increased clearance explains lower plasma levels of tissue-type plasminogen activator by estradiol: evidence for potently enhanced mannose receptor expression in mice
Blood
Danazol and stanozolol in long-term prophylactic treatment of hereditary angioedema
J Allergy Clin Immunol
Association of androgenic-anabolic steroid therapy with development of hepatocellular carcinoma
Lancet
Hepatic angiosarcoma associated with androgenic-anabolic steroids
Lancet
Danazol-induced cystitis: an undescribed source of hematuria in patients with hereditary angioneurotic edema
J Urol
Side effects of long-term prophylaxis with attenuated androgens in hereditary angioedema: comparison of treated and untreated patients
J Allergy Clin Immunol
Danazol therapy: an unusual aetiology of hepatocellular carcinoma
J Hepatol
Hepatocellular adenomas in patients taking Danazol for hereditary angiooedema
Lancet
Long-term treatment of hereditary angioedema with attenuated androgens: a survey of a 13-year experience
J Allergy Clin Immunol
Tranexamic acid and arterial thrombosis
Lancet
Tranexamic acid and intracranial thrombosis
Lancet
Replacement therapy in hereditary angioedema. Successful treatment of two patients with fresh frozen plasma
Lancet
Practical guidelines for the clinical use of plasma
Thromb Res
Danazol-induced hepatocellular adenoma in patients with hereditary angio-oedema
J Hepatol
Hereditary and acquired C-1 inhibitor deficiency: biological and clinical characteristics in 235 patients
Medicine (Baltimore)
Genetically determined heterogeneity of the C1 esterase inhibitor in patients with hereditary angioneurotic edema
J Clin Invest
Human C1 inhibitor: primary structure, cDNA cloning, and chromosomal localization
Biochemistry
Guest editor—editorial
Transfus Apheresis Sci
Cited by (0)
M. Cicardi has consultant arrangements with Dyax, Pharming, Jerini, and Aventis. C. Bucher is a consultant for ZLB Behring (formerly Aventis Behring). W. Kreuz has received grants–research support from Aventis Behring for research in the field of coagulation disorders and immune deficiencies. B. Zuraw has consultant arrangements with Dyax, Lev Pharmaceuticals, Aventis Behring, and Pharming. All other authors—no potential conflicts of interest disclosed.
- ∗
On behalf of PREHAEAT, European Concerted Action “Novel methods for predicting, preventing, and treating attacks in patients with hereditary angioedema.” Participants: Marco Cicardi, MD, Milan, Italy; Konrad Bork, MD, Mainz, Germany; Laurence Bouillet, MD, Grenoble, France; Anette Bygum, MD, Odense, Denmark; Henriette Farkas, MD, PhD, Budapest, Hungary; Erik Hack, MD, Amsterdam, The Netherlands; Margarita López-Trascasa, PhD, Madrid, Spain; Erik Waage Nielsen, MD, Bodö, Norway; Christoph Bucher, MD, Zürich, Switzerland; Lennart Truedsson, PhD, Lund, Sweden; and Hilary Longhurst, MD, London, United Kingdom.